# "Patologia neoplastica borderline della mammella"

Anna Sapino Department of Medical Sciences University of Torino (Italy)



# B3 Lesion of uncertain malignant potential

This category mainly consists of lesions which **may provide benign histology on CB**, but either are known to •show **heterogeneity** or •to have an **increased risk** (albeit low) of associated malignancy.

# Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Jacobs T, Connolly J, Schnitt, SJ Am J Surg Pathol 26(9): 1095–1110, 2002 columnar cell lesions atypical ductal hyperplasia lobular neoplasia (atypical lobular hyperplasia and lobular carcinoma in situ) papillary lesions radial scars









Am J Surg Pathol. 1998 Dec;22(12):1521-7.

Columnar alteration of lobules. This lesion is characterized by an enlarged lobule with slightly dilated The acini are lined by a single layer of

epithelial cells with elongated nuclei (B).











### The "Rosen Triad": Tubular Carcinoma, Lobular Carcinoma In Situ, and Columnar Cell Lesions

Suzanne M. Brandt, MD, Gloria Q. Young, MD, and Syed A. Hoda, MD Adv Anat Pathol. 2008 May;15(3):140-6









.m J Surg	Pathol 2007;31:417-426	Reported Genetic Changes					
	Lesions		Loss		Gain		1
ccc ↓	Contraction of the second	-16q	-19q	-11q	+16p +7	+19	+20 +15q
DIN1a							
DIN1b	60 885 F		-	-	-	-	
DIN1c	00		_	_	_	_	
Tubular Carcinoma	1 Contraction	-16q - 6p - 8p	-17p	-11q	-16p + 7 +17q	+8q +19 +1q	+20

Hormonal therapy for menopause and breast-cancer
risk by histological type: a cohort study and meta-
analysis.

Lancet Oncol. 2006 Nov;7(11):910-8

1.031.224 postmenopausal women recruited in 1996-2001

14 102 breast cancers

RR in current users compared with never users of hormone therapy

2.25 2.13 2.66 1.63 1.58 0.74	(95% CI 2.00-2.52) (95% CI 1.68-2.70) (95% CI 2.16-3.28) (95% CI 1.65-1.72) (95% CI 1.08-2.31) (95% CI 0.43-1.28)
2.13 2.66 1.63 1.58 0.74	(95% CI 1.68-2.70) (95% CI 2.16-3.28) (95% CI 1.55-1.72) (95% CI 1.08-2.31) (95% CI 0.43-1.28)
2.66 1.63 1.58 0.74	(95% CI 2.16-3.28) (95% CI 1.55-1.72) (95% CI 1.08-2.31) (95% CI 0 43-1 28)
1.63 1.58 0.74	(95% CI 1.55-1.72) (95% CI 1.08-2.31) (95% CI 0 43-1 28)
1.58 0.74	(95% CI 1.08-2.31) (95% CI 0 43-1 28)
0.74	(95% CI 0 43-1 28)
2.82	(95% CI 1.72-4.63)
1.56	(95% CI 1.38-1.75)
)	2.82 1.56



### ADH

- Page's view that the cellular changes of DCIS are present but occupy less than 2 separate duct spaces is widely accepted
- Others use a 2 mm cut-off; a lesion less than 2 mm in maximum dimension being classified as ADH and a larger area as DCIS (Tavassoli 1992).
- Others mention the involvement of a single TDLU.

These criteria recognise essentially the same lesions. In essence, ADH is usually small and focal, measuring less than 2 to 3 mm. Larger foci are accepted if associated with a radial scar/complex sclerosing lesion or a papilloma.





European Guidelines for quality assurance in breast cancer screening and diagnosis Fourth edition- Supplement 2012



- ADH is formed from a uniform population of small or medium-sized round, cuboidal or polygonal hyperchromatic cells, which are regularly arranged.
- The nuclei are evenly distributed and may form a rosette-like pattern. Single small nucleoli only are present. Mitoses, particularly abnormal forms, are infrequently seen.
- Geometric spaces are noted and, in the cribriform type, the cells are arranged at right angles to the bridges formed. Micropapillary ADH is also recognised and a solid pattern may very rarely be seen.
- Small foci of necrosis may rarely be identified in ADH and do not indicate that the process should be classified as DCIS





	UEH	ADH/low-grade DCIS					
Architecture							
a. Fenestrations	Peripheral and irregular	Central and 'punched out					
b. Streaming pattern	Present	Absent					
c. Nuclei	Prominent overlapping	Minimal overlapping					
Cellular features							
a. Cellular variation	Present	Monomorphic					
b. Cell margins	Indistinct	Distinct					
c. Nuclear variation	Present	Minimal					
. Immunoprofile							
a. Cytokeratins	Mixed luminal and basal	Luminal type only					
	type (CK7, CK19, CK5/6, CK14)	(CK7, CK18, CK19)					
b. Oestrogen receptor	Heterogeneous pattern	Homogeneous expression					
ADH is a clonal process, uniform phenotype and immunophenotype							









### CICATRICE SCLERO-ELASTOTICA

1- deposito di connettivo FIBRO-ELASTICO "cicatrice"

2- rari dotti con epitelio e mioepitelio inglobati

3- iperplasia o carcinoma in situ intorno alla cicatrice











### ADENOSI SCLEROSANTE

Usually incidental but may be a mass lesion Often associated calcs picked up on screening May be confused with cancers histologically Low power view critical to make correct diagnosis.....









# Atypical apocrine sclerosing lesion

Sclerosing adenosis lesion with superimposed apocrine metaplasia Atypia may be moderately severe - distinction from apocrine DCIS (with lobular cancerisation) may be difficult Immunostaining will demonstrate an intact myoepithelial layer and basement membrane Follow up of patients showed no greater cancer risk than other atypical lesions







well-defined margins and a surrounding lucent "halo"

well-defined, ovoid mass, predominantly solid appearance, but with a cystic component marked posterior acoustic enhancement





Background: debris +; histiocytes +; blood +;

Cellularity: +++ (poor if sclerotic); Large 3D sheets: ++

















Figure 8. Papillary ductal carcinoma *in situ* with dimorphic cell population. In addition to the neoplastic columnar epithelial cells covering the papillae, a second population of cells with pale cytoplasm is evident, primarily in a basal location. These cells ('globoid' cells) should not be mistaken for myoepithelial cells.

Singola fila di cellule epiteliali





Intracystic Papillary Carcinomas of the Breast: A Reevaluation Using a Panel of Myoepithelial Cell Markers Laura C. Collins, et al.

Am J Surg Pathol 2006;30:1002–1007



"Encapsulated Papillary Carcinoma"

circumscribed nodules of papillary carcinoma surrounded by a fibrous capsule in which a peripheral layer of MEC is not identifiable.



FNA: Carcinoma papillare intracistico/incapsula









### Intracystic/encapsulated papillary carcinoma

Am J Surg Pathol 2006;30:1002-1007



Available outcome data indicate that they have an excellent prognosis with adequate local therapy alone. We believe it is most prudent to continue to manage patients with these lesions as they are currently managed (ie, similar to patients with DCIS) and to avoid categorization of such lesions as frankly invasive papillary carcinomas.



The addition of radiation to the treatment of patients did not change the incidence of local recurrence or likelihood of death compared with those who did not receive radiation

Am J Surg. 2002;184:364-368

There has been no clear indication for adjuvant endocrine therapy, even among patients with estrogen receptor-positive tumors.

Furthermore, the addition of hormonal treatment does not appear to have impacted outcome.

Br J Surg. 1999;86:1274.

